- LimmaTech receives an exclusive clinical development license from AbVacc for a multivalent, toxoid vaccine candidate to prevent infections caused by Staphylococcus aureus, the leading cause of antimicrobial resistance-related deaths in the U.S. and Europe
- LimmaTech will initiate Phase 1 clinical development of the vaccine candidate in 2024 with an option to acquire full worldwide rights after the trial readout
Schlieren (Zurich) and Rockville (Maryland), December 19, 2023 – LimmaTech Biologics and AbVacc announced today a license agreement that grants LimmaTech the exclusive rights to further develop AbVacc’s multivalent toxoid vaccine candidate, LBT-SA7 (formerly IBT-V02), designed to prevent infections caused by the bacterial pathogen, Staphylococcus aureus (S. aureus). LimmaTech also receives an exclusive option, executable post Phase 1 read-out, to acquire full rights to the program. No further details of the transaction have been disclosed.